1. Home
  2. EWTX vs JBI Comparison

EWTX vs JBI Comparison

Compare EWTX & JBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EWTX
  • JBI
  • Stock Information
  • Founded
  • EWTX 2017
  • JBI 2002
  • Country
  • EWTX United States
  • JBI United States
  • Employees
  • EWTX N/A
  • JBI N/A
  • Industry
  • EWTX Biotechnology: Pharmaceutical Preparations
  • JBI Building Products
  • Sector
  • EWTX Health Care
  • JBI Industrials
  • Exchange
  • EWTX Nasdaq
  • JBI Nasdaq
  • Market Cap
  • EWTX 1.5B
  • JBI 1.2B
  • IPO Year
  • EWTX 2021
  • JBI N/A
  • Fundamental
  • Price
  • EWTX $14.63
  • JBI $9.12
  • Analyst Decision
  • EWTX Buy
  • JBI Buy
  • Analyst Count
  • EWTX 9
  • JBI 6
  • Target Price
  • EWTX $39.89
  • JBI $9.80
  • AVG Volume (30 Days)
  • EWTX 723.3K
  • JBI 989.5K
  • Earning Date
  • EWTX 08-07-2025
  • JBI 08-07-2025
  • Dividend Yield
  • EWTX N/A
  • JBI N/A
  • EPS Growth
  • EWTX N/A
  • JBI N/A
  • EPS
  • EWTX N/A
  • JBI 0.35
  • Revenue
  • EWTX N/A
  • JBI $919,800,000.00
  • Revenue This Year
  • EWTX N/A
  • JBI N/A
  • Revenue Next Year
  • EWTX N/A
  • JBI $5.69
  • P/E Ratio
  • EWTX N/A
  • JBI $25.80
  • Revenue Growth
  • EWTX N/A
  • JBI N/A
  • 52 Week Low
  • EWTX $10.60
  • JBI $5.99
  • 52 Week High
  • EWTX $38.12
  • JBI $15.24
  • Technical
  • Relative Strength Index (RSI)
  • EWTX 58.59
  • JBI 60.24
  • Support Level
  • EWTX $13.34
  • JBI $8.37
  • Resistance Level
  • EWTX $14.08
  • JBI $9.23
  • Average True Range (ATR)
  • EWTX 0.57
  • JBI 0.29
  • MACD
  • EWTX 0.16
  • JBI 0.01
  • Stochastic Oscillator
  • EWTX 98.60
  • JBI 74.26

About EWTX Edgewise Therapeutics Inc.

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

About JBI Janus International Group Inc.

Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.

Share on Social Networks: